Affiliation: Peter MacCallum Cancer Centre
- Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyGrant A McArthur
Peter MacCallum Cancer Centre, East Melbourne, Vic, Australia Electronic address
Lancet Oncol 15:323-32. 2014..We present an extended follow-up analysis of the total population and in the BRAF(V600E) and BRAF(V600K) mutation subgroups...
- Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012"Paolo A Ascierto
Istituto Nazionale Tumori, Fondazione G, Pascale, Naples, Italy
J Transl Med 11:137. 2013....
- Targeting oncogenic drivers and the immune system in melanomaGrant A McArthur
Division of Cancer Medicine and Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
J Clin Oncol 31:499-506. 2013....
- The granulocyte-colony stimulating factor receptor (G-CSFR) interacts with retinoic acid receptors (RARs) in the regulation of myeloid differentiationLynette C Y Chee
Research Division, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
J Leukoc Biol 93:235-43. 2013..However, with the loss of G-CSFR, this expansion in granulopoiesis was attenuated, supporting the hypothesis that G-CSFR signaling interacts with RARs in the regulation of myeloid differentiation...
- Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanomaGrant A McArthur
Peter MacCallum Cancer Centre, Melbourne, VIC 8006, Australia
J Clin Oncol 30:1628-34. 2012..We aimed to determine the metabolic response rate to vemurafenib in patients with advanced BRAF-mutant melanoma...
- Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancerSherene Loi
Department of Research, Molecular Oncology Lab, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
BMC Med Genomics 2:37. 2009..CONCLUSION: These data demonstrate that activation of GF signaling pathways, independent of HER2 over-expression, could be contributing to the poor prognosis of the luminal-B ER+ BC subtype...
- Splicing the way to leukemia with KITGrant A McArthur
Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
Leuk Lymphoma 49:1431-2. 2008
- Dermatofibrosarcoma protuberans: a surgical disease with a molecular saviorGrant A McArthur
Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
Curr Opin Oncol 18:341-6. 2006..This review will examine recent data confirming the central role of surgery in managing this disease and new findings for the application of molecularly targeted therapy in patients with unresectable disease...
- Dermatofibrosarcoma protuberans: recent clinical progressGrant McArthur
Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Australia, 3002
Ann Surg Oncol 14:2876-86. 2007....
- Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225Grant A McArthur
Peter MacCallum Cancer Centre, East Melbourne, Australia
J Clin Oncol 23:866-73. 2005..The purpose of this study was to evaluate molecular, cytogenetic, and kinase activation profiles in a series of DFSPs and to determine whether these biologic parameters are correlated with the clinical responses of DFSP to imatinib...
- Molecular targeting of dermatofibrosarcoma protuberans: a new approach to a surgical diseaseGrant A McArthur
Peter MacCallum Cancer Centre, East Melbourne, Australia
J Natl Compr Canc Netw 5:557-62. 2007....
- Molecularly targeted treatment for dermatofibrosarcoma protuberansGrant McArthur
Peter MacCallum Cancer Centre, East Melbourne, Australia
Semin Oncol 31:30-6. 2004..Imatinib may provide an alternative for the treatment of unresectable or partially resectable tumors, thereby possibly improving the effectiveness of surgery...
- Rate of growth in melanomas: characteristics and associations of rapidly growing melanomasWendy Liu
Victorian Melanoma Service, The Alfred Hospital, Melbourne, Australia
Arch Dermatol 142:1551-8. 2006..To investigate the spectrum of growth rates in melanomas and to identify clinical associations of rapidly growing melanomas...
- Sensitive detection of KIT D816V in patients with mastocytosisAngela Tan
Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia
Clin Chem 52:2250-7. 2006....
- The promise of PET in clinical management and as a sensitive test for drug cytotoxicity in sarcomasKenneth K Khamly
Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
Expert Rev Mol Diagn 8:105-19. 2008..This article will discuss the above issues, using the setting of sarcomas as an example...
- An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug developmentCarleen Cullinane
Sir Donald and Lady Trescowthick Laboratories and Center for Molecular Imaging, Peter MacCallum Cancer Center, Melbourn, Victoria, Australia
Cancer Res 65:9633-6. 2005..Further, the FDC-P1 model represents a very useful paradigm for molecularly targeted drug development...
- Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trialDanny Rischin
Department of Medical Oncology, Peter MacCallum Cancer Centre, A Beckett St, Locked Bag No 1, Melbourne 8006, Australia
J Clin Oncol 28:4142-8. 2010..To determine the prognostic importance of p16 and human papillomavirus (HPV) in patients with oropharyngeal cancer treated on a phase III concurrent chemoradiotherapy trial...
- Preclinical evaluation of nilotinib efficacy in an imatinib-resistant KIT-driven tumor modelCarleen Cullinane
Translational Research Laboratory, Research Division, East Melbourne, Victoria, Australia
Mol Cancer Ther 9:1461-8. 2010..These findings show the in vivo activity of nilotinib in the treatment of tumors bearing V560G-KIT but not D816V-KIT and the utility of FDG-PET imaging to assess tumor response to this agent...
- Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcomaDavid M Thomas
Ian Potter Foundation Centre for Cancer Genomics and Predictive Medicine, and Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Center, Victoria, Melbourne, Australia
J Cell Biol 167:925-34. 2004..Physiologic coupling of osteoblast differentiation to cell cycle withdrawal is mediated through runx2 and p27KIP1, and these processes are disrupted in osteosarcoma...
- Concurrent adjuvant radiotherapy and interferon-alpha2b for resected high risk stage III melanoma -- a retrospective single centre studyDavid E Gyorki
Peter MacCallum Cancer Centre, Skin and Melanoma Service, St Andrew s Place, East Melbourne, Victoria 3002, Australia
Melanoma Res 14:223-30. 2004..We conclude that concurrent use of adjuvant radiotherapy and IFNalpha2b may enhance radiation-induced toxicity. However, overall we found concurrent radiation and IFNalpha2b could be safely delivered with appropriate clinical monitoring...
- Imatinib as effective therapy for dermatofibrosarcoma protuberans: proof of concept of the autocrine hypothesis for cancerDespina Handolias
Peter MacCallum Cancer Centre, Department of Haematology and Medical Oncology, Locked Bag 1, A Beckett Street, Victoria 8006, Australia
Future Oncol 4:211-7. 2008..New insight into this fundamental biological mechanism sets the scene for the further development of molecular-targeted therapeutic options for cancer...
- Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposureDespina Handolias
Research Division Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria, Australia
Pigment Cell Melanoma Res 23:210-5. 2010..In the remaining cohort, 43% had chronically sun damaged skin. This report confirms that within an Australian population, KIT mutations are infrequent in cutaneous melanomas associated with both intermittent and chronic sun exposed skin...
- Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinomaSarah Jane Dawson
Department of Haematology and Medical Oncology, The University of Melbourne, Melbourne, Victoria, Australia
Anticancer Drugs 19:547-52. 2008..Sunitinib seems to be a promising agent in the treatment of thyroid cancers and this requires validation in future clinical trials...
- Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanomaBianca Devitt
Division of Cancer Medicine and Research, Peter MacCallum Cancer Centre, East Melbourne, Vic, Australia
Pigment Cell Melanoma Res 24:666-72. 2011..96; P = 0.04] but not BRAF(V600E) mutations (HR 1.73; P = 0.23). NRAS mutations were associated with thicker tumors and higher rates of mitosis when compared to BRAF(V600E) and WT melanoma and independently of this, with shorter MSS...
- Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancersAndrew J Deans
Trescowthick Research Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
Cancer Res 66:8219-26. 2006..Moreover, inhibitors of CDKs may be useful therapeutics in cancers with defects in DNA repair, such as mutations in the familial breast cancer gene BRCA1...
- EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptorBenjamin Solomon
Research Division, Department of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
Int J Radiat Oncol Biol Phys 55:713-23. 2003....
- Identification of the molecular requirements for an RAR alpha-mediated cell cycle arrest during granulocytic differentiationCarl R Walkley
Division of Research, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, Victoria, 3002, Australia
Blood 103:1286-95. 2004..Moreover, these data demonstrate selectivity among the RARs for cell cycle arrest pathways and provide a direct mechanism to link differentiation induction and regulation of the Myc antagonist Mad1...
- Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trialIan D Davis
Ludwig Oncology Unit, Austin Health, Melbourne, Victoria, Australia
Clin Cancer Res 15:2123-9. 2009..We report final clinical and biological results of a phase II study of recombinant human IL-21 (rIL-21) in patients with metastatic melanoma...
- Review: mucosal melanoma of the head and neckHaim Gavriel
Melanoma and Skin Service and Head and Neck Service, Division of Surgical Oncology, Department of Surgical Oncology, Peter MacCallum Cancer Center, Melbourne, Australia
Melanoma Res 21:257-66. 2011..We strongly recommend further evaluation of the role of chemotherapy and immunotherapy to decrease the rates of distant metastasis and improve survival...
- Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanomaWendy Liu
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
J Invest Dermatol 127:900-5. 2007..Although implicated in the control of the cell cycle, the BRAF(T1799A) mutation is associated with a lower rate of tumor proliferation...
- Cell division and hematopoietic stem cells: not always exhaustingCarl R Walkley
Research Division, Peter MacCallum Cancer Centre, Victoria, Australia
Cell Cycle 4:893-6. 2005..One of the emerging themes of these studies is that of the importance of cell cycle regulators in the maintenance of HSCs...
- Negative cell-cycle regulators cooperatively control self-renewal and differentiation of haematopoietic stem cellsCarl R Walkley
Research Division, Peter MacCallum Cancer Centre, Victoria 3002, Australia
Nat Cell Biol 7:172-8. 2005..Together these data demonstrate that the MYC-antagonist MAD1 and cyclin-dependent kinase inhibitor p27(Kip1) cooperate to regulate the self-renewal and differentiation of HSCs in a context-dependent manner...
- PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancerSherene Loi
Department of Research, Molecular Oncology Laboratory, Peter MacCallum Cancer Centre, East Melbourne 3002, Australia
Proc Natl Acad Sci U S A 107:10208-13. 2010..In ER+ BC cell lines, PIK3CA mutations were also associated with sensitivity to tamoxifen. These findings could have important implications for the treatment of PIK3CA-mutant BCs and the development of PI3K/mTOR inhibitors...
- MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiationGretchen Poortinga
Division of Research, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria, Australia
EMBO J 23:3325-35. 2004....
- mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBFKatherine M Hannan
Trescowthick Research Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, USA
Mol Cell Biol 23:8862-77. 2003..Thus, mTOR plays a critical role in the regulation of ribosome biogenesis via a mechanism that requires S6K1 activation and phosphorylation of UBF...
- UBF levels determine the number of active ribosomal RNA genes in mammalsElaine Sanij
Research Division, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
J Cell Biol 183:1259-74. 2008..We also show that the active rRNA gene pool is not static but decreases during differentiation, correlating with diminished UBF expression. Thus, UBF1 levels regulate active rRNA gene chromatin during growth and differentiation...
- Translational control of c-MYC by rapamycin promotes terminal myeloid differentiationMeaghan Wall
Division of Research, Peter MacCallum Cancer Centre, East Melbourne, Australia
Blood 112:2305-17. 2008..These findings suggest that mTORC1 could be targeted to promote terminal differentiation in myeloid malignancies characterized by dysregulated expression of c-MYC...
- An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanomaIan D Davis
Austin Health, Melbourne, Victoria, Australia
Clin Cancer Res 13:3630-6. 2007....
- Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033Donna S Dorow
Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Eur J Nucl Med Mol Imaging 33:441-52. 2006..This study was designed as "proof of concept" for a drug development model utilising multi-tracer serial small animal PET imaging to characterise tumour responses to molecularly targeted therapy...
- Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanomaTheo Nicholaou
Ludwig Institute for Cancer Research, Austin Health, Peter MacCallum Cancer Centre, CSL Limited, Melbourne, Victoria, Australia
Clin Cancer Res 15:2166-73. 2009..This study examines the clinical and immunologic efficacy of the same vaccine in patients with advanced metastatic melanoma...
- A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiencyCarl R Walkley
Trescowthick Research Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria, 3002, Australia
Cell 129:1097-110. 2007..These data show that loss of RARgamma results in a nonhematopoietic cell-intrinsic MPS, revealing the capability of the microenvironment to be the sole cause of hematopoietic disorders...
- Brca1 inactivation induces p27(Kip1)-dependent cell cycle arrest and delayed development in the mouse mammary glandAndrew J Deans
Molecular Oncology Laboratory, Trescowthick Research Laboratories, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne 3002, Australia
Oncogene 23:6136-45. 2004..We hypothesize that disruption of BRCA1 induces an increase in p27 that inhibits proliferation. Accordingly, reduction in p27 expression leads to enhancement of cellular proliferation in the absence of BRCA1...
- Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanomaMalcolm Ranson
Department of Medical Oncology, University of Manchester, United Kingdom
J Clin Oncol 25:2540-5. 2007....
- Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disordersMarianna David
Department of Haematology, University of Pecs, Pecs, Hungary
Blood 109:61-4. 2007..Our data show that durable hematologic and cytogenetic responses are achieved with imatinib in patients with PDGFRB fusion-positive, BCR-ABL-negative CMPDs...
- BRCA1-BARD1 complexes are required for p53Ser-15 phosphorylation and a G1/S arrest following ionizing radiation-induced DNA damageMegan Fabbro
Queensland Institute of Medical Research, Post Office Royal Brisbane Hospital, Brisbane, Queensland 4029, Australia
J Biol Chem 279:31251-8. 2004..These findings suggest that BRCA1-BARD1 complexes act as an adaptor to mediate ATM/ATR-directed phosphorylation of p53, influencing G(1)/S cell cycle progression after DNA damage...
- Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor)Michael C Heinrich
Oregon Health and Science University Cancer Institute and Portland VA Medical Center, Portland, OR, USA
J Clin Oncol 24:1195-203. 2006..To determine the clinical efficacy of imatinib in patients with advanced aggressive fibromatosis (AF) and to identify the molecular basis of response/nonresponse to this agent...
- IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinomaKlaus Stensgaard Frederiksen
Novo Nordisk A S, Novo Nordisk Park, Maalov, Denmark
Cancer Immunol Immunother 57:1439-49. 2008..Here we report the effects of systemic IL-21 therapy on the immune system in two phase 1 trials with this novel cytokine...
- MAD1 and p27(KIP1) cooperate to promote terminal differentiation of granulocytes and to inhibit Myc expression and cyclin E-CDK2 activityGrant A McArthur
Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Mol Cell Biol 22:3014-23. 2002..We conclude that Mad1 and p27(KIP1) operate, at least in part, by distinct mechanisms to downregulate CDK2 activity and Myc expression in order to promote cell cycle exit during differentiation...
- Correlation of subjective self-reported melanoma growth rate with objective tumor proliferation markersWenyuan Liu
Arch Dermatol 144:555-6. 2008
- Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndromeTara Seshadri
N Engl J Med 351:2134-5. 2004
- Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imagingBenjamin Solomon
Research Division, Peter MacCallum Cancer Institute, Melbourne, Australia
Mol Cancer Ther 4:1417-22. 2005..A strong correlation was observed between pimonidazole binding and FAZA uptake. Together, these findings show that gefitinib reduces intratumoral hypoxia...